0000000000397301

AUTHOR

Bulent Karadag

showing 2 related works from this author

The disease-specific clinical trial network for primary ciliary dyskinesia: PCD-CTN

2022

Primary ciliary dyskinesia; Rare genetic disorder; Lung diseases Discinesia ciliar primaria; Trastorno genético raro; Enfermedades pulmonares Discinesia ciliar primària; Trastorn genètic rar; Malalties pulmonars Primary ciliary dyskinesia (PCD) is a rare genetic disorder characterised by impaired mucociliary clearance leading to irreversible lung damage. In contrast to other rare lung diseases like cystic fibrosis (CF), there are only few clinical trials and limited evidence-based treatments. Management is mainly based on expert opinions and treatment is challenging due to a wide range of clinical manifestations and disease severity. To improve clinical and translational research and facili…

Pulmonary and Respiratory Medicine:enfermedades respiratorias::trastornos de la motilidad ciliar [ENFERMEDADES]:Health Occupations::Medicine::Pediatrics [DISCIPLINES AND OCCUPATIONS]Respiratory SystemSağlık BilimleriClinical Medicine (MED)SOLUNUM SİSTEMİRespiratory CareHealth SciencesMANAGEMENTKlinik Tıp (MED)Chest Diseases and Allergy:profesiones sanitarias::medicina::pediatría [DISCIPLINAS Y OCUPACIONES]:Otros calificadores::/terapia [Otros calificadores]:Respiratory Tract Diseases::Ciliary Motility Disorders [DISEASES]Internal Medicine SciencesScience & TechnologyKlinik TıpMUTATIONSRESPIRATORY SYSTEM:Other subheadings::/therapy [Other subheadings]Dahili Tıp BilimleriGöğüs Hastalıkları ve AllerjiCLINICAL MEDICINECèl·lules - Motilitat:Congenital Hereditary and Neonatal Diseases and Abnormalities::Genetic Diseases Inborn [DISEASES]TıpPulmons - Malalties - TractamentAkciğer ve Solunum TıbbıMedicineMalalties congènites:enfermedades y anomalías neonatales congénitas y hereditarias::enfermedades genéticas congénitas [ENFERMEDADES]Solunum BakımıLife Sciences & BiomedicinePulmons Malalties
researchProduct

Beliefs and preferences regarding biological treatments for severe asthma

2020

Background: Severe asthma is a serious condition with a significant burden on patients' morbidity, mortality, and quality of life. Some biological therapies targeting the IgE and interleukin-5 (IL5) mediated pathways are now available. Due to the lack of direct comparison studies, the choice of which medication to use varies. We aimed to explore the beliefs and practices in the use of biological therapies in severe asthma, hypothesizing that differences will occur depending on the prescribers’ specialty and experience. Methods: We conducted an online survey composed of 35 questions in English. The survey was circulated via the INterasma Scientific Network (INESNET) platform as well as throu…

Severe asthmaBehavior; Belief; Biological drug; Severe asthmainterleukine 5 IgEMULTICENTERDiseaseOmalizumabADD-ON THERAPYBehavior Belief Biological drug Severe asthmaDOUBLE-BLIND0302 clinical medicineMedicine and Health SciencesImmunology and AllergyEosinophil IL5 [Eos]030223 otorhinolaryngologyPulmonologistssevere asthma biological drug belief behavior3. Good healthBeliefSAFETYmedicine.druglcsh:Immunologic diseases. AllergyPulmonary and Respiratory Medicinemedicine.medical_specialtyEos: Eosinophil IL5ImmunologyBiological drugSpecialtylong-acting beta2-agonist OMASocio-culturaleSettore MED/10 - Malattie Dell'Apparato RespiratorioArticle03 medical and health sciencesQuality of life (healthcare)Omalizumab. OMA/IL5 Omalizumab plus anti-IL5 moleculeOMALIZUMABmedicineIntensive care medicineAsthmaBehaviorINterasma Scientific Network LABAbusiness.industryMEPOLIZUMABmedicine.diseaseEFFICACYICS inhaled corticosteroidsLIFE030228 respiratory systemImmunoglobulin E INESNETAllergistslcsh:RC581-607businessMepolizumab
researchProduct